Mwesigwa, Naome
Millar Vernetti, Patricio
Kirabo, Annet
Black, Bonnie
Ding, Tan
Martinez, Jose
Palma, Jose-Alberto
Biaggioni, Italo
Kaufmann, Horacio
Shibao, Cyndya A. http://orcid.org/0000-0002-4518-6801
Funding for this research was provided by:
U.S. Food and Drug Administration (R01 FD04778-02)
Center for Clinical and Translational Science, University of Illinois at Chicago (ULTR000445)
National Center for Research Resources FDA Office for Orphan Product Development (R01FD04778)
Article History
Received: 30 January 2024
Accepted: 27 June 2024
First Online: 19 September 2024
Declarations
:
: C.A. Shibao has received a research grant from the Doris Duke Foundation. I. Biaggioni, C.A. Shibao, and H. Kaufmann received grant support from the Office of Orphan Products Development. Food and Drug Administration, grant no. FD-R-04778–01-A3. C.A. Shibao has received a speaker honorarium from Lundbeck Pharmaceuticals. C.A. Shibao is the principal investigator of the trial funded by TheraVance Biopharma. H. Kaufmann is Editor-in-Chief of Clinical Autonomic Research, published by Springer-Nature, and serves as PI of studies sponsored by Biogen MA Inc. (TRACK MSA, S19-01846) and Vaxxinity Inc. (UB-312, S22-01332). He has received consultant fees from Takeda Pharmaceutical Company Ltd, Ono Pharma UK Ltd, Theravance Biopharma US Inc., and Parexel. He receives royalties from Up to Date. He receives research support from NIH-NINDS, the Food and Drug Administration, the Familial Dysautonomia Foundation, and the HSAN IV Foundation. I. Biaggioni is a consultant for Theravance Biopharma, Amneal Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, and Neurawell Therapeutics for the development of therapies for orthostatic hypotension and postural tachycardia syndrome. He is also a patent holder for an automated abdominal binder for the treatment of orthostatic hypotension and has submitted a patent application for the use of guanfacine for the treatment of Postural Tachycardia and Chronic Fatigue Syndromes. J.-A. Palma reports research funding from the NIH and salary from Eli Lilly. P.M. Vernetti has received funding from Theravance Biopharma for research related to nOH and is a principal investigator of the clinical trial (NCT05696717) funded by Theravance Biopharma for the development of ampreloxetine for nOH.